Current clinical management of gastrointestinal stromal tumors.

Alicia Tosoni, Linda Nicolardi, Alba A Brandes

Journal: Expert review of anticancer therapy 2004;4(4):595-605

PMID: 15270663

Abstract

Gastrointestinal stromal tumors (GIST) are defined as c-KIT-positive mesenchymal neoplasias located in the gastrointestinal tract and abdomen, most of which present an activating KIT mutation, a fundamental step in the development of disease. However, recent studies reported a small subgroup of KIT-negative GIST, in which platelet-derived growth factor receptor A, protein kinase C-tau, and FLJ10261 expression was detected. Imatinib (Gleevec, Novartis) is an orally administered competitive inhibitor of the tyrosine kinase domain of receptors such as KIT, ABL, and BCR-ABL fusion proteins, and the platelet-derived growth factor receptor. Phase I-III clinical trials have demonstrated the efficacy of imatinib in the treatment of metastatic GIST. However, the optimal dose and role of imatinib in an adjuvant or neoadjuvant setting have yet to be defined. Therefore, further studies investigating the mechanism of resistance to imatinib in patients with GIST are warranted.

Address: Department of Medical Oncology, Azienda Ospedale, University of Padova, Italy. [email protected]

DOI: 10.1586/14737140.4.4.595

Link outs

Free resources

Miscellaneous:

https://assays.cancer.gov/CPTAC-1776

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Oral, Antineoplastic Agents, Benzamides, Chemotherapy, Adjuvant, Clinical Trials as Topic, Disease Progression, Gastrointestinal Neoplasms, Humans, Imatinib Mesylate, Isoenzymes, Piperazines, Protein Kinase C, Protein Kinase C-theta, Proto-Oncogene Proteins c-kit, Pyrimidines, Receptor, Platelet-Derived Growth Factor alpha, Stromal Cells, Zinc Fingers